Form 4: REGENXBIO CTO Malzahn's RSU Tax Withholding

REGENXBIO's Chief Technology Officer, Craig Malzahn, reported a disposition of 234 common shares for tax withholding purposes related to RSU vesting.

Summary

• Craig Malzahn, Chief Technology Officer of REGENXBIO Inc. (RGNX), reported a transaction on September 1, 2025.
• The transaction involved the disposition of 234 shares of common stock at a price of $8.93 per share.
• This disposition was for the purpose of withholding shares to cover tax obligations upon the vesting of restricted stock units (RSUs).
• The RSUs were originally granted to Mr. Malzahn on September 1, 2022.
• Following this transaction, Mr. Malzahn beneficially owns 17,585 shares of REGENXBIO common stock directly.
• The number of shares withheld was determined based on the closing price of REGENXBIO's common stock on August 29, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction (tax withholding for RSU vesting) by an insider. It is neutral in sentiment as it reflects an expected part of executive compensation rather than a discretionary buy or sell decision based on new information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a tax withholding event related to RSU vesting. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine, non-discretionary event and is unlikely to have a significant direct impact on shareholders. It represents a minor change in insider ownership.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary tax withholding transaction by a company officer upon RSU vesting. It does not provide any new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for a buy or sell decision.

Keywords

REGENXBIO, RGNX, Craig Malzahn, Chief Technology Officer, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, tax withholding, common stock